TerminatedPhase 3ACTRN12606000085572

Dexmedetomidine and Haloperidol for the management of emergence delirium in intensive care


Sponsor

Prince of Wales Hospital

Enrollment

60 participants

Start Date

Mar 1, 2006

Study Type

Interventional

Conditions


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying: Dexmedetomidine and Haloperidol for the management of emergence delirium in intensive care. It may be open to adults aged 18 and older who meet certain criteria, including: Requiring invasive ventilation for longer than 24 hours. Participation typically involves medical assessments, possible treatment with the study intervention, and follow-up visits to track your health.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Patients will be randomised to receive IV Haloperidol 5 mg 6 hourly after loading

Patients will be randomised to receive IV Haloperidol 5 mg 6 hourly after loading


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12606000085572